Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:42AM ET
0.4099
Dollar change
-0.0092
Percentage change
-2.20
%
Index- P/E- EPS (ttm)-0.55 Insider Own36.78% Shs Outstand23.67M Perf Week2.47%
Market Cap10.62M Forward P/E- EPS next Y-0.47 Insider Trans-0.23% Shs Float16.38M Perf Month-21.63%
Income-11.57M PEG- EPS next Q- Inst Own7.94% Short Float6.19% Perf Quarter-39.72%
Sales0.48M P/S22.13 EPS this Y32.73% Inst Trans-11.95% Short Ratio2.60 Perf Half Y-3.28%
Book/sh-0.07 P/B- EPS next Y-28.38% ROA-181.08% Short Interest1.01M Perf Year-81.11%
Cash/sh0.04 P/C9.66 EPS next 5Y- ROE-703.62% 52W Range0.36 - 2.92 Perf YTD-38.29%
Dividend Est.- P/FCF- EPS past 5Y30.13% ROI- 52W High-85.96% Beta1.47
Dividend TTM- Quick Ratio0.40 Sales past 5Y141.81% Gross Margin13.84% 52W Low13.86% ATR (14)0.03
Dividend Ex-Date- Current Ratio0.40 EPS Y/Y TTM12.19% Oper. Margin-2206.67% RSI (14)45.71 Volatility5.36% 9.00%
Employees20 Debt/Eq- Sales Y/Y TTM-64.72% Profit Margin-2425.79% Recom2.00 Target Price4.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q46.97% Payout- Rel Volume1.27 Prev Close0.42
Sales Surprise-91.05% EPS Surprise-20.00% Sales Q/Q-87.74% EarningsMar 27 AMC Avg Volume389.16K Price0.41
SMA20-3.38% SMA50-7.66% SMA200-51.30% Trades Volume115,384 Change-2.20%
Date Action Analyst Rating Change Price Target Change
Apr-16-21Downgrade Dawson James Buy → Neutral
Today 05:58AM
Mar-27-24 08:53PM
04:00PM
Mar-20-24 07:00AM
Mar-13-24 07:00AM
07:00AM Loading…
Mar-12-24 07:00AM
Mar-04-24 09:27AM
08:00AM
Feb-08-24 07:00AM
Jan-31-24 07:00AM
Jan-03-24 07:00AM
Dec-19-23 07:00AM
Dec-18-23 07:16AM
Nov-29-23 07:00AM
Nov-16-23 12:56PM
11:04AM Loading…
Nov-15-23 11:04AM
Nov-14-23 07:15AM
Nov-09-23 12:48PM
06:59AM
Nov-08-23 05:52PM
05:50PM
04:11PM
Nov-01-23 05:04PM
Oct-12-23 11:08AM
Oct-11-23 06:00AM
Sep-06-23 10:31AM
07:15AM
Sep-05-23 07:15AM
Aug-11-23 09:29AM
Aug-09-23 06:05PM
04:05PM Loading…
04:05PM
Aug-02-23 07:00AM
Jul-24-23 07:00AM
Jul-10-23 08:11AM
Jul-05-23 07:00AM
Jun-20-23 05:14PM
Jun-08-23 07:00AM
May-28-23 08:08AM
May-23-23 07:00AM
May-12-23 06:06AM
May-10-23 05:45PM
04:05PM
May-09-23 07:00AM
May-03-23 08:00PM
Apr-28-23 07:00AM
Apr-04-23 07:00AM
Apr-01-23 12:47PM
Mar-31-23 06:05AM
Mar-29-23 08:15AM
Mar-16-23 07:00AM
Mar-06-23 01:06PM
07:00AM
Feb-01-23 06:30AM
Jan-31-23 05:39AM
Dec-22-22 07:00AM
Dec-21-22 05:07AM
Dec-15-22 07:00AM
Dec-06-22 07:00AM
Nov-09-22 05:35PM
04:05PM
12:00PM
Nov-02-22 05:31PM
Oct-03-22 01:33PM
07:00AM
Sep-14-22 07:00AM
Sep-09-22 07:00AM
Sep-08-22 07:00AM
Sep-06-22 11:03AM
Aug-31-22 07:00AM
Aug-24-22 09:40AM
07:00AM
Aug-10-22 05:15PM
04:30PM
04:05PM
Aug-04-22 02:04PM
Aug-01-22 08:00AM
Jul-12-22 08:15AM
Jun-15-22 08:00AM
May-11-22 05:55PM
04:15PM
May-06-22 03:15PM
May-04-22 08:30AM
Apr-13-22 10:25AM
Apr-12-22 07:15AM
Mar-30-22 03:51PM
Mar-29-22 04:05PM
Mar-24-22 08:00AM
Mar-22-22 08:30AM
Mar-01-22 08:00AM
Feb-14-22 07:30AM
Feb-03-22 02:53PM
08:00AM
Jan-10-22 08:00AM
Dec-15-21 08:00AM
Nov-10-21 04:30PM
Nov-08-21 04:30PM
Nov-02-21 03:02PM
Oct-21-21 07:30AM
Oct-12-21 08:00AM
Oct-07-21 08:00AM
BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Altman PeterPresident and CEOFeb 13 '24Buy0.46108,10850,000555,447Feb 15 07:00 AM
FROST PHILLIP MD ET AL10% OwnerJan 19 '24Sale0.43129,80255,8151,896,025Jan 22 08:38 PM
Altman PeterPresident and CEOMay 26 '23Buy1.606,2009,920469,239May 30 05:01 PM